BioCentury | Dec 22, 2008
Company News

AAIPharma, Cortria deal

...Cortria received an exclusive license to use AAIPharma's ProCR controlled-release drug delivery technology with TRIA-662 in...
...treat dyslipidemia with data expected in early 2009. Cortria has rights to develop and commercialize TRIA-662...
BioCentury | Jul 21, 2008
Company News

Cortria, Pharmena deal

...The companies cross-licensed each other’s assets related to Pharmena’s TRIA-662 . The metabolite of niacin is...
...with data expected in early 2009. Cortria received an exclusive license to develop and commercialize TRIA-662...
Items per page:
1 - 2 of 2